S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:PSTV

Plus Therapeutics (PSTV) Stock Price, News & Analysis

$1.80
-0.05 (-2.70%)
(As of 03/28/2024 ET)
Today's Range
$1.76
$1.85
50-Day Range
$1.63
$2.23
52-Week Range
$0.97
$5.10
Volume
41,388 shs
Average Volume
32,493 shs
Market Capitalization
$7.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Plus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
454.0% Upside
$10.00 Price Target
Short Interest
Healthy
0.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.12mentions of Plus Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.99) to ($1.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.90 out of 5 stars

PSTV stock logo

About Plus Therapeutics Stock (NASDAQ:PSTV)

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

PSTV Stock Price History

PSTV Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Q4 2023 Plus Therapeutics Inc Earnings Call
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Plus Therapeutics Inc PSTV
Plus Updates Financial and Cash Guidance for 2024
Why Plus Therapeutics Stock Popped Today
See More Headlines
Receive PSTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
3/28/2024
Next Earnings (Estimated)
4/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PSTV
Employees
20
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+454.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-13,320,000.00
Net Margins
-271.04%
Pretax Margin
-271.04%

Debt

Sales & Book Value

Annual Sales
$4.91 million
Book Value
($0.30) per share

Miscellaneous

Free Float
4,177,000
Market Cap
$7.73 million
Optionable
Not Optionable
Beta
0.60

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Marc H. Hedrick M.B.A. (Age 61)
    M.D., President, CEO & Director
    Comp: $945.34k
  • Mr. Andrew J. Sims C.P.A. (Age 51)
    VP of Finance & CFO
    Comp: $498.51k
  • Dr. Norman D. LaFrance FACNP (Age 76)
    FACP, M.D., Chief Medical Officer & Senior VP
    Comp: $646.02k
  • Ms. Desiree Smith (Age 60)
    Corporate Controller, Principal Financial & Accounting Officer
  • Dr. John K. Fraser (Age 63)
    Chief Scientist

PSTV Stock Analysis - Frequently Asked Questions

Should I buy or sell Plus Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Plus Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PSTV shares.
View PSTV analyst ratings
or view top-rated stocks.

What is Plus Therapeutics' stock price target for 2024?

1 brokers have issued twelve-month price targets for Plus Therapeutics' shares. Their PSTV share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 454.0% from the stock's current price.
View analysts price targets for PSTV
or view top-rated stocks among Wall Street analysts.

How have PSTV shares performed in 2024?

Plus Therapeutics' stock was trading at $1.7501 on January 1st, 2024. Since then, PSTV shares have increased by 3.1% and is now trading at $1.8050.
View the best growth stocks for 2024 here
.

Are investors shorting Plus Therapeutics?

Plus Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 32,200 shares, a drop of 21.1% from the February 29th total of 40,800 shares. Based on an average daily trading volume, of 34,300 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.8% of the company's stock are short sold.
View Plus Therapeutics' Short Interest
.

When is Plus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 18th 2024.
View our PSTV earnings forecast
.

How were Plus Therapeutics' earnings last quarter?

Plus Therapeutics, Inc. (NASDAQ:PSTV) issued its earnings results on Tuesday, March, 5th. The company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.78) by $0.08. The firm had revenue of $1.31 million for the quarter, compared to the consensus estimate of $1.26 million. Plus Therapeutics had a negative trailing twelve-month return on equity of 805.57% and a negative net margin of 271.04%.

When did Plus Therapeutics' stock split?

Shares of Plus Therapeutics reverse split on the morning of Monday, May 1st 2023. The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Plus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Plus Therapeutics investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Chimerix (CMRX), Genocea Biosciences (GNCA), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Aileron Therapeutics (ALRN) and CymaBay Therapeutics (CBAY).

Who are Plus Therapeutics' major shareholders?

Plus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.76%), Vanguard Group Inc. (0.72%) and Citadel Advisors LLC (0.37%). Insiders that own company stock include Andrew John Hugh Macintyr Sims, Azeez Hayne, Greg Petersen, Howard Clowes, Marc H Hedrick, Marc H Hedrick, Richard J Hawkins and Robert P Lenk.
View institutional ownership trends
.

How do I buy shares of Plus Therapeutics?

Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PSTV) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners